NASDAQ: KTTA
Pasithea Therapeutics Corp Stock Ownership - Who owns Pasithea Therapeutics?

Insider buying vs selling

Have Pasithea Therapeutics Corp insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Simon DumesnilDirector2025-11-2833,333$0.75
$25.00kBuy
Emer LeahyDirector2025-11-2833,333$0.75
$25.00kBuy
Tiago MarquesChief Executive Officer2025-11-2833,333$0.75
$25.00kBuy
Daniel H. SchneidermanChief Financial Officer2025-11-2826,667$0.75
$20.00kBuy
Lawrence SteinmanDirector2025-11-28133,333$0.75
$100.00kBuy

1 of 1

KTTA insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when KTTA insiders and whales buy or sell their stock.

KTTA Shareholders

What type of owners hold Pasithea Therapeutics Corp stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Coastlands Capital LP11.18%3,735,035$2.70MInsider
Pd Joint Holdings LLC Series 2016a7.81%2,608,696$1.88MInsider
Squadron Capital Management LLC6.28%2,100,000$1.52MInstitution
Vivo Capital LLC6.28%2,100,000$1.52MInstitution
Adage Capital Partners GP LLC6.28%2,100,000$1.52MInstitution
Janus Henderson Group PLC6.28%2,100,000$1.52MInstitution
Eric Shahinian5.35%1,788,415$1.29MInsider
Ameriprise Financial Inc4.04%1,350,896$975.35kInstitution
Cable Car Capital LP3.61%1,206,379$871.01kInstitution
Israel Maxx Abramowitz3.15%1,051,575$759.24kInsider

1 of 3

KTTA vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
KTTA38.36%38.68%Net Buying
MRKR2.76%97.24%
JSPR24.49%75.51%Net Buying
SNSE16.16%83.84%Net SellingNet Buying
PLUR0.02%99.98%Net BuyingNet Buying

Pasithea Therapeutics Stock Ownership FAQ

Who owns Pasithea Therapeutics?

Pasithea Therapeutics (NASDAQ: KTTA) is owned by 38.36% institutional shareholders, 38.68% Pasithea Therapeutics insiders, and 22.96% retail investors. Coastlands Capital LP is the largest individual Pasithea Therapeutics shareholder, owning 3.74M shares representing 11.18% of the company. Coastlands Capital LP's Pasithea Therapeutics shares are currently valued at $2.69M.

If you're new to stock investing, here's how to buy Pasithea Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.